ClinicalTrials.gg
RecruitingNCT07536542Updated Jun 2, 2026

Effects of Dual-Task Training on Upper Extremity Function in Parkinson's Disease

An interventional study of Dual-Task Training in Parkinson Disease (PD), sponsored by Ankara University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by Ankara University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 172 studies in Parkinson Disease with a site in Turkey — 50 open to participants now, 56 under way, none of them phase 3. Parkinson Disease · Turkey.

Planned enrollment
43rd of 99
38 · median 32
Started
2026
with 28 others
No phase
92 of 172
26 open now
Primary completion
2026-07
later than 26 of 55 live
Registered
151st of 172
by date
Lead sponsor
6 of 172
Ankara University

Among the 172 studies in Parkinson Disease with a site in Turkey, this one is the 43rd largest by planned enrollment of the 99 interventional ones that give a count, is one of 29 that started in 2026, is one of 92 with no phase, reaches primary completion later than 26 of the 55 other live ones, and was the 151st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

50 of the 172 studies in Parkinson Disease with a site in Turkey are open now. Recruiting first, the newest first:

44 more — sign in →

All 50 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 172 studies in Parkinson Disease with a site in Turkey, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate the effects of dual-task training on upper extremity function and muscle thickness in individuals with Parkinson's disease. The main questions it aims to answer are:

Does dual-task training improve upper extremity function in individuals with Parkinson's disease? Does dual-task training lead to changes in upper extremity muscle thickness measured by ultrasonography?

Researchers will compare a dual-task training group with a control group receiving routine care to determine whether 8 weeks of dual-task training results in greater improvements in upper extremity outco

Participants will:

complete baseline and post-intervention assessments of upper extremity function, muscle thickness, grip strength, and pinch strength be assigned to either a control group or a dual-task training group receive dual-task training 3 days per week for 8 weeks if assigned to the intervention group

03

Conditions studied

  • Parkinson Disease (PD)

Browse trials for

Keywords

  • Parkinson Disease
  • Dual-Task Training
  • Upper Extremity Function
  • Muscle Thickness
  • Ultrasonography
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of idiopathic Parkinson's disease confirmed by a neurologist
  • Modified Hoehn and Yahr stage 2 to 3
  • No medication or dosage change within the last 6 months
  • Cognitive capacity sufficient to understand and follow instructions, defined as score ≥21
  • Voluntary participation with written

Exclusion criteria

Exclusion Criteria:

  • Atypical or secondary parkinsonism
  • Advanced orthopedic condition affecting the upper extremity
  • Surgery, trauma, or immobilization involving the upper extremity within the last 6 months
  • Wound or dermatological condition preventing upper extremity ultrasonographic evaluation
  • Severe visual or hearing loss
  • Severe depression, psychosis, or communication difficulty
  • Any additional health problem preventing regular participation in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
38 participants (estimated)

Study arms

  • Experimental
    Dual-Task Training Group

    Participants will receive dual-task training in addition to their routine daily activities. The training program will be performed 3 times per week for 8 weeks, with each session lasting 60 minutes and consisting of combined motor and cognitive tasks.

    Behavioral: Dual-Task Training

  • No intervention
    Control Group

    Participants will continue their routine daily activities without receiving any additional exercise, training, or rehabilitation intervention during the study period.

Interventions

  • BehavioralDual-Task Training

    Dual-task training will be applied 3 times per week for 8 weeks, with each session lasting 60 minutes. The program combines motor tasks (such as peg placement, object manipulation, bilateral coordination, and mobility tasks) with simultaneous cognitive tasks (such as backward counting, category-based word generation, and memory tasks).

06

What researchers measure

Primary outcomes

  1. Upper Extremity Function

    Upper extremity function will be assessed using the Purdue Pegboard Test. Performance will be recorded as the number of pins placed within the specified time for dominant hand, nondominant hand, and both hands; higher scores indicate better fine motor performance and manual dexterity.

    Time frame: Baseline and 8 weeks

  2. Upper Extremity Muscle Thickness

    Muscle thickness of the deltoid, biceps brachii, triceps brachii, and forearm flexor muscles will be measured using ultrasonography. The mean of three repeated measurements for each site will be recorded in millimeters.

    Time frame: Baseline and 8 weeks

  3. Hand Grip Strength

    Hand grip strength will be measured using a Jamar hydraulic hand dynamometer according to the ASHT protocol. The mean of three trials will be recorded.

    Time frame: Baseline and 8 weeks

  4. Pinch Strength

    Lateral pinch, three-jaw chuck pinch, and two-point pinch strength will be assessed using a pinch meter. The mean of three trials will be recorded in kilograms or Newtons.

    Time frame: Baseline and 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2026, 3 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 3 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2026
First posted
Apr 17, 2026
StartActual
Apr 24, 2026
Primary completionEst.
Jul 24, 2026
CompletionEst.
Aug 1, 2026
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07536542
Lead sponsor
Ankara University
Responsible party
Büşra Seçkinoğulları Korkusuz (Assist. Prof. Dr, Ankara University) — Principal investigator
First posted
Apr 17, 2026
Start date
Apr 24, 2026
Primary completion
Jul 24, 2026 (estimated)
Completion
Aug 1, 2026 (estimated)
Last update
Jun 2, 2026

Study contacts

Büşra Seçkinoğulları Korkusuz, PhD
Contact
bskorkusuz@ankara.edu.tr
+905442436914
Büşra Seçkinoğulları Korkusuz
principal investigator · Ankara University
Süleyman Korkusuz
study chair · Atılım University
Ayşenur Özcan
study chair · Çankırı Karatekin University
Ayla Fil
study chair · Hacettepe University
Gül Yalçın Çakmaklı
study chair · Hacettepe University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion